Pages that link to "Q34847863"
Jump to navigation
Jump to search
The following pages link to Demethylating agents in myeloid malignancies (Q34847863):
Displaying 50 items.
- Epigenetics of colorectal cancer (Q24598045) (← links)
- Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents (Q24633763) (← links)
- Epigenetic Therapeutics: A New Weapon in the War Against Cancer (Q28072370) (← links)
- Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial (Q28294892) (← links)
- Acute erythroleukemia: diagnosis and management (Q28298763) (← links)
- Established and emerging targeted therapies in the myelodysplastic syndromes (Q30245476) (← links)
- Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives (Q30570945) (← links)
- Differentiation therapy of leukemia: 3 decades of development (Q33409795) (← links)
- A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms (Q33502760) (← links)
- The aberrant asynchronous replication - characterizing lymphocytes of cancer patients - is erased following stem cell transplantation (Q33585868) (← links)
- Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications (Q33610854) (← links)
- DNA methylation in glioblastoma: impact on gene expression and clinical outcome (Q33771159) (← links)
- Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer (Q33782392) (← links)
- DNA hypomethylation in cancer cells (Q33862334) (← links)
- Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies (Q33980682) (← links)
- Methylation silencing of ULK2, an autophagy gene, is essential for astrocyte transformation and tumor growth (Q34070445) (← links)
- Decitabine in the treatment of myelodysplastic syndromes. (Q34088403) (← links)
- Microarray-based DNA methylation study of Ewing's sarcoma of the bone (Q34141451) (← links)
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients (Q34398397) (← links)
- DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target (Q34412280) (← links)
- Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. (Q34480576) (← links)
- Epstein-Barr virus-specific methylation of human genes in gastric cancer cells (Q34504229) (← links)
- Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes (Q35043089) (← links)
- IL-2R common γ-chain is epigenetically silenced by nucleophosphin–anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK (Q35123227) (← links)
- Characterization of a 5-azacytidine-induced developmental Aspergillus fumigatus variant. (Q35693769) (← links)
- Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. (Q35835233) (← links)
- Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review. (Q36294643) (← links)
- C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. (Q36498110) (← links)
- Functional DNA demethylation is accompanied by chromatin accessibility (Q36769429) (← links)
- Microdeletion syndromes disclose replication timing alterations of genes unrelated to the missing DNA. (Q37139251) (← links)
- Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy. (Q37249131) (← links)
- Human T-cell leukemia virus type I-mediated repression of PDZ-LIM domain-containing protein 2 involves DNA methylation but independent of the viral oncoprotein tax. (Q37350642) (← links)
- Chromatin maps, histone modifications and leukemia. (Q37423780) (← links)
- Laromustine (cloretazine). (Q37693943) (← links)
- Drug transporter pharmacogenetics in nucleoside-based therapies. (Q37760954) (← links)
- Myelodysplastic Syndromes: What a Primary Care Physician Needs to Know (Q37783729) (← links)
- New nucleoside analogs for patients with hematological malignancies (Q37841589) (← links)
- Epigenetic alterations in autoimmune rheumatic diseases (Q37846094) (← links)
- Management of lower-risk myelodysplastic syndromes: the art and evidence. (Q37858436) (← links)
- Epigenomic deregulation in the immune system. (Q37962605) (← links)
- Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies (Q37963498) (← links)
- Epigenetic-based therapies in cancer: progress to date (Q37964702) (← links)
- Cutaneous lymphomas: molecular pathways leading to new drugs (Q37967108) (← links)
- Novel immune modulators used in hematology: impact on NK cells (Q38073760) (← links)
- Epigenetics of melanoma: implications for immune-based therapies. (Q38148588) (← links)
- Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. (Q38327984) (← links)
- Epigenetic Determinants of Cancer (Q38837858) (← links)
- Anti-neoplastic properties of hydralazine in prostate cancer (Q38998403) (← links)
- Sweet's syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine (Q39137715) (← links)
- Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA (Q39620587) (← links)